All News
Filter News
Found 806,087 articles
-
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
3/27/2024
Nutriband Inc. provided an overview of the clinical development and regulatory pathway for its lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions Space
3/27/2024
Sumitomo Chemical Co., Ltd. and Valent BioSciences LLC announced that Pace International LLC and its operations overseas will become part of AgroFresh Solutions, Inc., a well-established leader in the postharvest solutions space.
-
Merrimack Receives $225 Million Milestone Payment from Ipsen
3/27/2024
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
-
Tevogen Bio Announces Series A-1 Preferred Stock Investment
3/27/2024
Tevogen Bio Holdings has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
-
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
3/27/2024
Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.
-
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
3/27/2024
TFF Pharmaceuticals, Inc. announced updated data from the Tacrolimus Inhalation Powder and Voriconazole Inhalation Powder clinical programs.
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
3/27/2024
Moderna, Inc. announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline.
-
Xcell Biosciences Announces New Scientific and Business Advisory Board
3/27/2024
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
-
Stephanie Burke Named as VGXI's New Chief Accounting Officer
3/27/2024
VGXI, Inc., a leading contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, is pleased to announce the appointment of Stephanie Burke as the Chief Accounting Officer for VGXI.
-
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
3/27/2024
Vaccinex, Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant.
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
3/27/2024
Avalo Therapeutics, Inc. announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc.
-
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
3/27/2024
Blackstone announced a new collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza program.
-
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
3/27/2024
Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.
-
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
3/27/2024
TellBio, Inc. announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.
-
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
3/27/2024
argenx SE announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease, following the analysis of topline data from the Phase 2 RHO study.
-
New Scientific Publication Shows LB-100, Lixte’s Lead Clinical Compound, Can Force Cancer Cells to Give Up Their Cancer-Causing Properties
3/27/2024
LIXTE Biotechnology Holdings, Inc. announced publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - March 27, 2024
3/27/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.
-
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2024
3/27/2024
Neuronetics, Inc. announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock to eleven new non-executive employees.
-
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
3/27/2024
Santhera Pharmaceuticals announces that the China National Medical Products Administration has accepted for priority review the new drug application for vamorolone in Duchenne muscular dystrophy which was submitted by Sperogenix Therapeutics, Santhera's specialized rare disease partner for China.